Forte Biosciences, Inc. (FBRX)Healthcare | Biotechnology | Dallas, United States | NasdaqCM
76.99 USD
|
Hot Take ↕ | Aug. 22, 2026, 4:34 a.m. EDT
Forte Biosciences presents a classic high-risk biotech scenario where a recent catalyst—positive Phase 1b data—has propelled the stock to its 52-week high, yet the underlying financials remain unprofitable with negative cash flow and earnings. The short-term outlook leans slightly bullish due to strong technical momentum and the recent rally, but the analyst consensus targets a lower price, creating tension. Long-term, the eight-year price history shows a severe decline, though the most recent annual period ended positive, leaving the investment case neutral. There is no dividend income to offset the capital risk. Investors should treat this as a speculative trade on clinical progress rather than a fundamental value play. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.259455 |
| AutoARIMA | 0.277506 |
| AutoETS | 0.277510 |
| AutoTheta | 0.292797 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 21% |
| H-stat | 7.31 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 1.03 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 1,634,427,392 |
| Forward P/E | -18.89 |
| Beta | 2.65 |
| Website | https://www.fortebiorx.com |
As of Aug. 22, 2026, 4:34 a.m. EDT: Speculators are positioning for continued volatility with heavy put open interest at lower strikes (50 to 55) acting as a hedge against a pullback from current highs, while call open interest clusters near the current price level (80) and further out-of-the-money. Implied volatility remains low across expirations, suggesting the market is not pricing in a significant immediate crash despite the defensive positioning.
| Attribute | Value |
|---|---|
| 52 Week Change | 5.9990907 |
| Address1 | 3,060 Pegasus Park Drive |
| Address2 | Building 6 |
| All Time High | 6,732.375 |
| All Time Low | 4.11 |
| Ask | 98.52 |
| Ask Size | 2 |
| Average Analyst Rating | 2.5 - Buy |
| Average Daily Volume10 Day | 1,739,952 |
| Average Daily Volume3 Month | 1,362,558 |
| Average Volume | 1,362,558 |
| Average Volume10Days | 1,739,952 |
| Beta | 2.645 |
| Bid | 76.99 |
| Bid Size | 42 |
| Book Value | 7.52 |
| City | Dallas |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 76.99 |
| Current Ratio | 10.01 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 77.0 |
| Day Low | 76.96 |
| Display Name | Forte Biosciences |
| Dividend Date | 1,592,265,600 |
| Earnings Timestamp End | 1,794,227,400 |
| Earnings Timestamp Start | 1,794,227,400 |
| Ebitda | -94,721,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -18.376 |
| Enterprise Value | 1,740,604,672 |
| Eps Current Year | -4.48 |
| Eps Forward | -4.075 |
| Eps Trailing Twelve Months | -4.57 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 54.0 |
| Fifty Day Average Change | 22.989998 |
| Fifty Day Average Change Percent | 0.4257407 |
| Fifty Two Week Change Percent | 599.90906 |
| Fifty Two Week High | 77.2 |
| Fifty Two Week High Change | -0.20999908 |
| Fifty Two Week High Change Percent | -0.0027201956 |
| Fifty Two Week Low | 10.11 |
| Fifty Two Week Low Change | 66.88 |
| Fifty Two Week Low Change Percent | 6.6152325 |
| Fifty Two Week Range | 10.11 - 77.2 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,492,090,200,000 |
| Float Shares | 18,667,811 |
| Forward Eps | -4.075 |
| Forward P E | -18.893251 |
| Free Cashflow | -41,293,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 23 |
| Fullday Change | 0.0 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 76.99 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0164 |
| Held Percent Institutions | 0.96650004 |
| Implied Shares Outstanding | 21,229,087 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,724,803,200 |
| Last Split Factor | 1:25 |
| Long Business Summary | Forte Biosciences, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for autoimmune and autoimmune-related diseases. The company offers products, such as its lead product candidate FB102, a proprietary molecule with applications for celiac disease, vitiligo, and alopecia areata; and services, including the clinical development and management of its Phase 2 clinical trials. Forte Biosciences, Inc. was incorporated in 2007 and is based in Dallas, Texas. As of August 27, 2026, Forte Biosciences, Inc. operates as a subsidiary of argenx SE. |
| Long Name | Forte Biosciences, Inc. |
| Market | us_market |
| Market Cap | 1,634,427,392 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_594626683 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -87,937,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,634,427,408 |
| Number Of Analyst Opinions | 4 |
| Open | 76.97 |
| Operating Cashflow | -71,976,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 310 618 6994 |
| Previous Close | 76.99 |
| Price Eps Current Year | -17.185266 |
| Price Hint | 2 |
| Price To Book | 10.238031 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.822 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.5 |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 77.0 |
| Regular Market Day Low | 76.96 |
| Regular Market Day Range | 76.96 - 77.0 |
| Regular Market Open | 76.97 |
| Regular Market Previous Close | 76.99 |
| Regular Market Price | 76.99 |
| Regular Market Time | 1,787,774,400 |
| Regular Market Volume | 1,399,801 |
| Return On Assets | -0.37794 |
| Return On Equity | -0.62277 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 21,229,087 |
| Shares Percent Shares Out | 0.0769 |
| Shares Short | 1,632,328 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 2,060,636 |
| Short Name | Forte Biosciences, Inc. |
| Short Percent Of Float | 0.0774 |
| Short Ratio | 0.82 |
| Source Interval | 15 |
| State | TX |
| Symbol | FBRX |
| Target High Price | 77.0 |
| Target Low Price | 61.0 |
| Target Mean Price | 73.0 |
| Target Median Price | 77.0 |
| Total Cash | 198,460,000 |
| Total Cash Per Share | 7.88 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.57 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 32.957134 |
| Two Hundred Day Average Change | 44.032864 |
| Two Hundred Day Average Change Percent | 1.3360647 |
| Type Disp | Equity |
| Volume | 1,399,801 |
| Website | https://www.fortebiorx.com |
| Zip | 75,247 |